Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders
Location: United States, New York
Investors 2
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | CRG | crglp.com |
Mentions in press and media 2
| Date | Title | Description |
| 07.06.2017 | How a company could disrupt billion-dollar drug markets with a single pill | Reuters/Brian Snyder An injection Advertisement Many of the powerful drugs used to treat autoimmune diseases have to be injected. Protagonist Therapeutics wants to change that, instead of using the same approach but in a pill. The potential... |
| 09.12.2016 | Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M | Synergy Pharmaceuticals $SGYP is following up on the late-stage success of its lead drug plecanatide for chronic idiopathic constipation with a new batch of upbeat Phase III data centered on irritable bowel syndrom... |